Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: Implications for male hormonal contraception

Journal of Andrology

Volumn 29, Issue 3, 2008, Pages 260-271

  Amory, John K ^a,b   Kalhorn, Thomas F ^a   Page, Stephanie T ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

5 reductase; Androgens; FSH; LH; Male fertility

Indexed keywords

ANDROSTANOLONE; CREATININE; DUTASTERIDE; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; TESTOSTERONE ENANTATE;

ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GASTROINTESTINAL REFLUX; HEADACHE; HEMATOCRIT; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; LIBIDO DISORDER; LIVER FUNCTION TEST; LOADING DRUG DOSE; MALE; MALE FERTILITY; MOOD CHANGE; MORNING DOSAGE; ORGASM DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SPERMATOGENESIS; STOMACH PAIN; UPPER RESPIRATORY TRACT INFECTION; VIVID DREAM;

ADULT; AFFECT; AZASTEROIDS; CONTRACEPTIVE AGENTS, MALE; DOUBLE-BLIND METHOD; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; LUTEINIZING HORMONE; MALE; SEXUAL BEHAVIOR; TESTOSTERONE;

EID: 43449138233     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.107.004226     Document Type: Article

References (25)

1. Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride: a pharmacokinetic study in men. J Clin Endocrinol Metab. 2005;90:2610-2617.
2. Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: pharmacokinetic effects of 5α reduction with finasteride or dutasteride and food intake in men. J Androl. 2006;27:72-78.
3. Amory JK, Wang C, Swerdloff R, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV. The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92:1659-1665.
4. Bagatell CJ, Bahl KD, Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. J Androl. 1994;15:15-21.
5. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996;81:757-762.
6. Brady DM, Amory JK, Perheentupa A, Zitzmann M, Hay C, Apter D, Anderson RA, Bremner WJ, Huhtaniemi I, Nieshclag E, Wu FCW, Kersemaekers WM. A multi-centre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod. 2006;21:285-294.
7. Canovatchel WJ, Volquez D, Huang S, Wood E, Lesser MI, Gautier T, Imperato-McGinley J. Luteinizing hormone pulsatility in subjects with 5-alpha-reductase deficiency and decreased dihydrotestosterone production. J Clin Endocrinol Metab. 1994;78:916-921.
8. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179-2184.
9. Hayes FJ, Decruz S, Seminara SB, Boepple PA, Crowley WF. Differential regulation of gonadotorpin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J Clin Endocrinol Metab. 2001;86:53-58.
10. Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 2000;85:3027-3035.
11. Heckel MJ. Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med. 1939;40:658-659.
12. Heinemann K, Saad F, Wiesemes M, White S, Heinemann L. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod. 2005;20:549-556.
13. Kalhorn TF, Page ST, Howald WN, Mostaghel EA, Nelson PS. Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:3200-3206.
14. Marberger M. Drug insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol. 2006;3:495-503.
15. Martin CW, Anderson RA, Chang L, Ho PC, van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT. Potential impact of hormonal male contraception: cross-cultural implications for development of novel male preparations. Hum Reprod. 2000;15:637-645.
16. Matthiesson KL, McLachlan RI. Male hormonal contraception: concept proven, product in sight? Hum Reprod Update. 2006;12:463-482.
17. McNair DM, Lorr M, Droppleman LF. Profile of Mood States: Manual. San Diego, CA: Education and Industrial Testing Service; 1971.
18. O'Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry MJ. Brief male sexual function inventory for urology. Urology. 1995;46:697-706.
19. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS. The importance of dual 5alpha-reductastse inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55:1014-1023.
20. Otberg N, Finner WM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am. 2007;36:379-398.
21. Page ST, Amory JK, Anawalt BD, Irwig M, Brockenbrough A, Matsumoto AM, Bremner WJ. Testosterone gel combined with depomedroxyprogesterone acetate (DMPA) is an effective male hormonal contraceptive regimen but is not enhanced by the addition of the GnRH antagonist acyline. J Clin Endocrinol Metab. 2006;91:4374-4380.
22. Riley SA, Sutcliffe F, Kim M, Kapas M, Rowland M, Turnberg LA. The influence of gastrointestinal transit on drug absoprtion in healthy volunteers. Br J Clin Pharmacol. 1992;34:32-39.
23. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224.
24. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, Lucas G, Hull L, Swerdoff RS. Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab. 2004;89:2936-2941.
25. Weston GC, Schlipalious ML, Bhuinneasin MN, Vollenhoven BJ. Will Australian men use male hormonal contraception? Med J Aust. 2002;175:204-205.